Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial w/ open-label extension (Apeldoorn et al, 2024) adds to previous ketamine findings

Escrito por Michael DeMarco
Michael DeMarco

Psychedelic therapist, clinical sexologist, and Founding Fellow of Psychedelic Institute of Mental Health and Family Therapy / Consultor en Medicina Psicodélica, sexólogo clínico y miembro fundador del Instituto Psicodélico SAS

https://psychedelicmentalhealth.net/michael-demarco-therapist
Anterior

American Journal of Nursing recommends Cognitive Behavioral Therapy Training for Treatment Resistant Schizophrenia (2022)
Siguiente

Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study (Aday, et al, 2024)